Aarkstore - Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Sterling Justin

Description

Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Breast Cancer.
Browse full report @ http://bit.ly/1wgFgSu

Informations

• Publié par: JustinSterling
• Publié le: 26 février 2015
• Nombre de lectures: 1
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

Aarkstore Enterprise

Aarkstore - Metastatic Breast Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Browse Full Report @

http://www.aarkstore.com/pharmaceuticals-healthcare/98049/metastatic-breast-cancer-global- api-manufacturers-marketed-and-phase-iii-drugs-landscape-2015

Synopsis

Published:Feb 2015|No. Of Pages:100 Pages

PDF:$ 2000|Site Licence: $ 4000|Enterprise Wide Licence: $ 6000

Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Breast Cancer. A key objective of DelveInsights report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Metastatic Breast Cancer. The Report gives insights into patents providing thepatent protection data and marketing exclusivity of all the drugs across the Metastatic Breast Cancer. While the leading brands, companies and chemicals are considered thoroughly, DelveInsights report also provides details on the Global API Manufacturersacross the globe coveringDrug Master FilingsofUS, Europe and API Manufacturers in Asia specifically China and India. The researchanalysis also presents the global sales forecasts data till 2016.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Aarkstore Enterprise

Scope

 

 











  

A snapshot of the global Market therapeutics scenario for Metastatic Breast Cancer. A review of the marketed products under prescription for Metastatic Breast Cancer, regulatory information and marketing status. Coverage of global patent coverage and detailed commentaries on the US patent challenges. Graphical representation of investigational products for patent expiry and market exclusivities across the globe. Product profiles for marketed products for Metastatic Breast Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. Coverage of API Manufacturers for Metastatic Breast Cancer drugs in the United States, Europe and Asian Regions with location details. Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Metastatic Breast Cancer drugs. Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Metastatic Breast Cancer drugs. Coverage of Metastatic Breast Cancer Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress. Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs. Key discontinued Marketed products. Global Sales Figure from 2012-2016.

Reasons To Buy









 

  

Evaluate the marketing status and exclusivity details of Metastatic Breast Cancerkey products to exploit opportunities for generic drug development opportunities. Identify and understand important and diverse types of therapeutics under Phase III development for Metastatic Breast Cancer. Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Metastatic Breast Cancer. API intelligence over marketed drugs forMetastatic Breast Cancerand gaining primary intelligence over active ingredients manufacturers across the globe. API intelligence over leading Phase III Pipeline drugs. Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope. Understanding the scope of the Phase III Drugs with nil regulatory filings. Understanding the chemical route of synthesis of approved drugs for Metastatic Breast Cancer. Uncovering opportunities in the rapidly growing US market.

Aarkstore Enterprise

Browse complete Report on:

http://www.aarkstore.com/pharmaceuticals-healthcare/98049/metastatic-breast-cancer- global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-2015

Table of Content

                          

Indication Overview

Marketed Drugs

Marketed Details of Drugs by Application Type Marketed Details of Drugs (NDA) by Marketing Status Marketed Details of Drugs by Patent Expiration Timeline

Active Pharmaceutical Ingredient (API) Manufacturers Assessment API Manufacturers by United States Drug Master File (US DMF) Status API Manufacturers by US DMF Status (Drug Specific)

API Manufacturers in Europe by Country

API Manufacturers in India by State

API Manufacturers in China by Province

Marketed Details of Approved Drugs by Geography Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs API Manufacturers by US DMF Status (Drug Specific)

Drugs Market Data and Forecasted Sales Figure (2012-2016)

Marketed Drugs for Metastatic Breast Cancer Drug Name Drug Description

Global Active Pharmaceutical Manufacturers for Drug

Approval Status of Drug

Patent and Exclusivity Details for Drug

Company Profile and Financials Phase III Drugs for Metastatic Breast Cancer United States Drug Master File (DMF)

Discontinued Drugs for Metastatic Breast Cancer Appendix Methodology

Aarkstore Enterprise

 

Contact Us Disclaimer

List of Tables

             

Metastatic Breast Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2015 Metastatic Breast Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015 Metastatic Breast Cancer Therapeutic Market, US, (Year), 2015

Metastatic Breast Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2015 Metastatic Breast Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015 Metastatic Breast Cancer Drugs, API Manufacturers, Europe by Country, 2015 Metastatic Breast Cancer Drugs, API Manufacturers, India by State, 2015 Metastatic Breast Cancer Drugs, API Manufacturers, China by Province, 2015

Metastatic Breast Cancer Drugs, API Manufacturers by Geography 2015 Metastatic Breast Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2015 Metastatic Breast Cancer Therapeutic Market, Global Sales 2012-2016 (in million USD)

API Manufacturers for Drug, 2015

Phase III Drugs for Metastatic Breast Cancer, 2015 Discontinued Drugs for Metastatic Breast Cancer, 2015

List of Figures

Metastatic Breast Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015 Metastatic Breast Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015

Metastatic Breast Cancer Therapeutic Market, US, (Year), 2015

Metastatic Breast Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2015

Metastatic Breast Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015 Metastatic Breast Cancer Drugs, API Manufacturers, Europe by Country, 2015 Metastatic Breast Cancer Drugs, API Manufacturers, India by State, 2015 Metastatic Breast Cancer Drugs, API Manufacturers, China by Province, 2015 Metastatic Breast Cancer Drugs, API Manufacturers by Geography 2015 Metastatic Breast Cancer Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2015

Aarkstore Enterprise

Metastatic Breast Cancer Therapeutic Market, Global Sales 2012-2016 (in million USD) Drug, Patent/Exclusivity Expiry (Year), 2015

Related reports:

Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Global Patient Temperature Management Market 2015-2019

Global Infertility Market 2015-2019

Global Preventable Vaccines Market 2015-2019

Global Transplantation Market 2015-2019

Global Ultrasound Equipment Market 2015-2019

Cystic Fibrosis Market in Europe 2015-2019

Global Cell Culture Protein Surface Coating Market 2015-2019

Global Infertility Market 2015-2019

Generic Drugs Market in Japan 2015-2019

About Aarkstore Enterprise

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.

Contact Details:

Aarkstore Enterprise

Phone: [phone]

Email:[e-mail]

Our Website:http://www.aarkstore.com